Prestige Consumer Healthcare Inc
NYSE:PBH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prestige Consumer Healthcare Inc
Net Income (Common)
Prestige Consumer Healthcare Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
Net Income (Common)
$186.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$21B
|
CAGR 3-Years
18%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
$7.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$20.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
27%
|
CAGR 10-Years
24%
|
|
Prestige Consumer Healthcare Inc
Glance View
Prestige Consumer Healthcare Inc. has carved out its niche in the competitive realm of over-the-counter healthcare products with a distinct flair. Born out of a series of insightful acquisitions and strategic brand cultivations, the company has crafted a portfolio that caters to a broad spectrum of consumer health needs. It offers an expansive range of products, from well-known pain relievers and eye care items to gastrointestinal treatments and women’s health solutions. The cornerstone of Prestige's success lies in its acute understanding of consumer demand and its agile response to market trends. By developing and acquiring brands that are established household names—such as Clear Eyes, Chloraseptic, and Dramamine—the firm has effectively secured a reliable revenue stream. Each brand, while under the corporate umbrella of Prestige, thrives on its ability to resonate with consumers who seek trustworthy, easily accessible remedies. Central to Prestige’s business model is its adeptness at maintaining and enhancing brand equity. Through a blend of focused marketing strategies and disciplined cost management, the company ensures consistent visibility and availability of its products across key retail channels, including mass merchandisers, drug retailers, and e-commerce. Prestige's skillful navigation of the marketplace allows it to capitalize on scale economies and maintain healthy margins. Each product in its portfolio is not only a testament to its commitment to quality and efficacy but also to its strategic foresight in addressing the ever-evolving healthcare challenges faced by consumers. In essence, Prestige Consumer Healthcare Inc. thrives by blending astute brand management with a keen focus on consumer health trends, ensuring its position as a formidable player in the healthcare industry.
See Also
What is Prestige Consumer Healthcare Inc's Net Income (Common)?
Net Income (Common)
186.5m
USD
Based on the financial report for Dec 31, 2025, Prestige Consumer Healthcare Inc's Net Income (Common) amounts to 186.5m USD.
What is Prestige Consumer Healthcare Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
5%
Over the last year, the Net Income (Common) growth was -13%. The average annual Net Income (Common) growth rates for Prestige Consumer Healthcare Inc have been -4% over the past three years , 2% over the past five years , and 5% over the past ten years .